Welcome to our dedicated page for AGENUS SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AGENUS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AGENUS's regulatory disclosures and financial reporting.
Agenus (AGEN) reported an insider stock compensation event. Chairman and CEO Garo H. Armen received 4,216 shares of Common Stock on 10/17/2025 as salary paid in stock, in lieu of cash, under the Amended and Restated 2019 Equity Incentive plan. The grant was valued using the $3.88 closing price on 10/17/2025 and the shares were fully vested at issuance.
Following the transaction, Dr. Armen beneficially owns 286,609 shares directly, plus 31,298 shares indirectly held in IRA accounts and 28,950 shares indirectly via trust/partnership interests as described in the footnotes.
Agenus Inc. entered into a Promissory Note Agreement with Zydus Pharmaceuticals (USA) Inc. for up to $10,000,000 of short-term funding. The note bears 3.81% annual interest and is due at the closing of previously signed asset and securities purchase agreements with Zydus, or within ten days after notice that those deals will not close.
Proceeds will support operating expenses at Agenus’s Emeryville and Berkeley facilities during the fourth quarter of 2025 and to make certain payments related to assets covered by the asset purchase agreement. The facility-related fourth-quarter funding will be forgiven and not repaid if the transactions with Zydus are completed. As collateral, Agenus pledged 822,910 shares of MiNK Therapeutics, Inc. common stock, which are expected to be released once the note is repaid or forgiven.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,951 shares of common stock as salary in lieu of cash, issued under the company's equity plan. The shares were issued at the closing price of $4.14 on 10/03/2025 and are fully vested on issuance. After the transaction, Dr. Armen directly beneficially owns 282,393 shares, with additional indirect holdings of 31,298 and 28,950 through retirement accounts and trusts/partnership interests respectively. The filing notes that the stock payment was approved by the Compensation Committee and represents the net amount for the payroll period ending 10/03/2025.
Agenus Inc. (AGEN) director Thomas L. Harrison received 5,780 shares of common stock on 10/01/2025 under the company's Board Compensation Election Policy, electing to take director fees in equity rather than cash. The shares were issued at an average price of $5.01, which the filer says is the average closing price for the quarter preceding issuance. After this transaction, Mr. Harrison beneficially owns 22,079 shares. The Form 4 was filed by an attorney-in-fact on 10/03/2025, and no derivative transactions are reported.
Timothy R. Wright, a director of Agenus Inc. (AGEN), reported acquiring 1,704.928 deferred stock units on 10/01/2025 under the company’s Amended and Restated Directors' Deferred Compensation Plan. Each deferred stock unit converts to one share of common stock on a 1-for-1 basis, and the filing shows 21,872.43 shares beneficially owned by Mr. Wright after the transaction. The filing notes that a prior tranche of deferred stock units was valued at $5.01 per unit on 7/01/2025, and states the October 1, 2025 unit price is the average closing price for the company’s common stock during the calendar quarter immediately preceding that date. The units are typically distributed under the Plan once the director ceases service.
Agenus Inc. reported an update on its previously announced transactions with Zydus Pharmaceuticals (USA) Inc., involving the sale of its manufacturing operations, a minority equity investment by Zydus, and a license granting Zydus commercial rights in India and Sri Lanka for BOT/BOL-related intellectual property. The companies had already submitted an initial filing to the Committee on Foreign Investment in the United States (CFIUS).
On September 17, 2025, CFIUS requested that Agenus and Zydus voluntarily submit a full notice application for these transactions. As a result of the expected timing of this extended CFIUS review, Agenus now anticipates that the closing of the transactions will occur in the fourth quarter of 2025 rather than earlier.
Garo H. Armen, Chairman and CEO of Agenus Inc. (AGEN), reported a non-derivative acquisition on 09/19/2025. At his request and with Compensation Committee approval, Mr. Armen’s salary for the pay period ending September 19, 2025, was paid in stock: 3,734 shares of Common Stock were issued at a closing price of $4.38. Those shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on issuance. Following the transaction the filing shows Mr. Armen beneficially owning 278,442 shares directly, 31,298 shares held in his IRA accounts, and 28,950 shares indirectly through trustee and partnership arrangements. The form was signed by an attorney-in-fact on 09/23/2025.
Garo H. Armen, Chairman and CEO of Agenus Inc. (AGEN), received 3,778 shares of common stock as payment of salary for the pay period ending September 5, 2025. The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on issuance. The report shows a per-share value of $4.33, the closing price on September 5, 2025. Following this issuance, Dr. Armen beneficially owns 274,708 shares directly and additional indirect holdings reported as 31,298 and 28,950 shares held in IRA accounts and other vehicles described in the footnotes. The Form 4 was signed by an attorney-in-fact on behalf of Dr. Armen on September 8, 2025.
Garo H. Armen received 3,619 shares of Agenus Inc. common stock as salary in lieu of cash for the pay period ending August 22, 2025. The shares were issued at a closing price of $4.52 on August 22, 2025, and are fully vested on issuance under the company's amended 2019 Equity Incentive plan. After the reported issuance, Dr. Armen is shown as beneficial owner of 270,930 shares directly, plus indirect holdings of 31,298 and 28,950 shares tied to his IRA accounts and other entities where he holds trustee or partnership roles.
The Form 4 reflects routine insider compensation reporting rather than an open-market purchase or sale; the filing was signed by an attorney-in-fact on August 25, 2025. Explanatory footnotes state the stock issuance was approved by the Agenus Compensation Committee and represents net salary for the stated payroll period.
Agenus Inc. reported a six-month net loss of $56.4 million and a weighted average basic and diluted loss per share of $2.03. Cash and cash equivalents were $9.5 million at June 30, 2025, and the company had an accumulated deficit of $2.2 billion and total assets of $185.2 million. The balance sheet shows a large recorded liability related to sale of future royalties and milestones, net of $312.2 million, current liabilities of $234.6 million and stockholders’ deficit attributable to Agenus of $354.6 million.
The company received $75.0 million gross proceeds from the Ligand Purchase Agreement (allocated partly to a royalty liability) and recognized $48.4 million of non-cash royalty revenue in the six months. Subsequent to quarter end it sold ~787,000 shares for net proceeds of ~$5.2 million and expects to receive $75.0 million upfront plus a $16.0 million equity investment from the Zydus transaction upon closing in Q3 2025. Management discloses substantial doubt about going concern for one year after filing and notes ongoing litigation and an SEC subpoena.